ReviewBiotechnology journal2015
Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.
Review in Biotechnology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Collagen nanofiber reinforced alginate hydrogel tube microbioreactors for cell culture.Frontiers in bioengineering and biotechnology · 2026Article
- Advances of Green-Synthesized Nanoparticles for Biomedical Applications.BioMed research international · 2026Review
- Collagen hydrogel tube microbioreactors for cell and tissue manufacturing.Biofabrication · 2025Article
- Enabling Mesenchymal Stromal Cells and Their Extracellular Vesicles Clinical Availability-A Technological and Economical Evaluation.Journal of extracellular biology · 2025Article
- Engineering of Trophoblast Extracellular Vesicle-Delivering Hydrogels for Localized Tolerance Induction in Cell Transplantation.Cellular and molecular bioengineering · 2023Article
- A scalable culture system incorporating microcarrier for specialised mesenchymal stem cells from human embryonic stem cells.Materials today. Bio · 2023Article
- Dedifferentiated fat cells administration ameliorates abnormal expressions of fatty acids metabolism-related protein expressions and intestinal tissue damage in experimental necrotizing enterocolitis.Scientific reports · 2023Article
- Fabricating 3-dimensional human brown adipose microtissues for transplantation studies.Bioactive materials · 2023Article
- Comparative study of differentiating human pluripotent stem cells into vascular smooth muscle cells in hydrogel-based culture methods.Regenerative therapy · 2023Article
- Bioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products.Bioengineering (Basel, Switzerland) · 2022Review
- Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies.NPJ Regenerative medicine · 2022Article
- Advances in hPSC expansion towards therapeutic entities: A review.Cell proliferation · 2022Review
- Improving three-dimensional human pluripotent cell culture efficiency via surface molecule coating.Frontiers in chemical engineering · 2022Article
- Dynamic Culture of Mesenchymal Stromal/Stem Cell Spheroids and Secretion of Paracrine Factors.Frontiers in bioengineering and biotechnology · 2022Review
- Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic.NPJ Regenerative medicine · 2021Review
- Comparative Study of Human Pluripotent Stem Cell-Derived Endothelial Cells in Hydrogel-Based Culture Systems.ACS omega · 2021Article
- Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors.Stem cell research & therapy · 2021Article
- Advanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy.Advanced functional materials · 2020Article
- Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors.Stem cells translational medicine · 2020Article
- Human Cell Atlas and cell-type authentication for regenerative medicine.Experimental & molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to develop cost-effective, scalable and robust bioprocesses for human pluripotent stem cells (hPSCs) will be key to their commercial success as cell therapies and tools for use in drug screening and disease modelling studies. This review outlines key process economic drivers for hPSCs and progress made on improving the economic and operational feasibility of hPSC bioprocesses. Factors influencing key cost metrics, namely capital investment and cost of goods, for hPSCs are discussed. Step efficiencies particularly for differentiation, media requirements and technology choice are amongst the key process economic drivers identified for hPSCs. Progress made to address these cost drivers in hPSC bioprocessing strategies is discussed. These include improving expansion and differentiation yields in planar and bioreactor technologies, the development of xeno-free media and microcarrier coatings, identification of optimal bioprocess operating conditions to control cell fate and the development of directed differentiation protocols that reduce reliance on expensive morphogens such as growth factors and small molecules. These approaches offer methods to further optimise hPSC bioprocessing in terms of its commercial feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.